Stardots and BrainZell Launch Cross-AI to Link Human Measurements With Neural Organoid Research

Stardots and BrainZell have established Cross-AI, a research collaboration exploring how drug responses in patient-derived neural organoids relate to measurements in people, with bipolar disorder as the initial research direction. The companies announced the collaboration on October 26, 2026, according to news.cision.com.

How the Cross-AI Collaboration Works

BrainZell will draw on Stardots' existing Psilmi research platform as a human reference within its own organoid research workflow. Psilmi combines synchronized measurements of pupil dynamics, eye movements and cognitive performance. The collaboration brings together Stardots' human-measurement, platform and AI expertise with BrainZell's organoid, electrophysiology, experimental and AI expertise.

The name Cross-AI reflects cross-scale artificial intelligence, connecting human-level measurements from Psilmi with cellular-level activity in BrainZell's neural organoid models. The research begins with BrainZell's high-throughput organoid arrays, used to explore biological targets and test compounds. The companies' AI teams will work together on linking laboratory response patterns with Psilmi measurements, including signals unfolding on different time scales.

A selected subset of participants could provide matched human and organoid data. Psilmi's underlying dataset comes from a research project at Uppsala University, and Stardots accesses it through collaboration with the university. Any use in the programme, including matched data, remains subject to consent, ethics, data-protection and donor-governance review.

"Psilmi brings pupil responses, eye movements and cognitive performance together in one research platform. We are pleased to work with BrainZell to connect those human measurements with complementary cellular models," says Daniel Petrini, CEO, Stardots.

"This collaboration brings us closer to one of the greatest goals of drug development: predicting patient outcomes from preclinical models," says Petra Szeszula, CEO, BrainZell.

BrainZell develops patient-derived neural organoid models and assays for investigating neural biology and drug responses. On August 18, 2026, Navinci Diagnostics and BrainZell announced a collaboration to test Navinci's in situ Proximity Ligation Assay in human brain organoids, news.cision.com reported.

Organoid Partnerships Across the Sector

Okomera signed a commercial agreement with Servier on October 21, 2026, to use its tumor miniaturization technology for cancer research, FinancialContent Business Page reported. Helmholtz Munich and Parse Biosciences announced a partnership on October 20, 2026, to generate a human lung tissue perturbation atlas using Parse's GigaLab platform, AETOSWire reported. CTIBIOTECH signed a strategic partnership and MOU with Beijing Vital River on October 15, 2026, to commercialize its 3D bioprinted human tissue bioassays in China, FinancialContent Business Page reported. Medera's Novoheart contributed its human cardiac technologies to Singapore's CIPHER centre, launched on October 16, 2026, Business & Financial reported.

Early-Stage Research and Next Steps

While the collaboration builds on existing technologies, the combined human-organoid approach is still in the early stages of research. Any predictive or clinical applications would require further validation and, where applicable, regulatory review. The partners aim to help pharmaceutical teams identify promising drug candidates, stratify trial participants, and measure treatment response.